During the recent earnings call, Sartorius AG (SARTF) executives provided valuable insights into the company’s performance and future prospects. CFO Florian Funck highlighted the 12-month rolling book-to-bill ratio as a key indicator of order trends, reassuring investors about the stability of the business.
CEO Michael Grosse expressed confidence in the company’s guidance, especially in the Bioprocess Solutions (BPS) segment, while acknowledging challenges in Lab Products & Services (LPS). With a 6% growth in group revenue and a significant increase in EBITDA margins, Sartorius AG’s performance reflects its strong position in the biotech industry. The company’s focus on innovation and efficiency, as evidenced by the launch of new products, bodes well for its future growth. Stay updated on Sartorius AG’s progress by referring to the full earnings call transcript.
Read more from finance.yahoo.com